Value Investor
Start free

Oric Pharmaceuticals

ORIC on Nasdaq. Pharmaceutical preparations. Market value $1.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-9.0%low

For every $100 of what the whole company costs, it produced $-9.04 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$11.98 a share, 66% above its 1-year low

Over the past year the price has ranged from $7.23 to $14.93.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
2021202220232024202512 monthsto Jun '26
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
0.04n/an/an/an/a
Shares outstanding
0.04bn0.05bn0.07bn0.10bn0.10bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 162% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $41 million, compared with a loss of $36 million a year ago.
  • Over the past 12 months it spent $112 million more cash than it brought in, compared with $121 million a year earlier.
  • 38% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$35m
December 2024-$36m
March 2025-$30m
June 2025-$36m
September 2025-$33m
December 2025-$31m
March 2026-$36m
June 2026-$41m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
23 February 2026
Next quarterly (estimated, 10-Q)
2 November 2026

Who owns it

2 long-term investors we follow own it, unchanged from 2 last quarter. 181 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

12 investors own more than 5%.

  • Ott David C.
    Passive investor
    10.0%+0.8 pts
    Since 30 June 2025
  • Nextech Crossover I GP S.a. r.l.
    Passive investor
    at least 8.4%
    (filed with 4 related holders)
    Since 30 June 2025
  • Viking Global Investors
    Passive investor
    at least 7.8%−2.2 pts
    (filed with 9 related holders)
    Since 31 March 2026
  • EcoR1 Capital, LLC
    Passive investor
    at least 6.9%
    (filed with 2 related holders)
    Since 29 July 2025
  • BlackRock, Inc.
    Passive investor
    5.6%+1.4 pts
    Since 31 December 2025
  • 5.4%
    Since 31 March 2026
  • SR One Capital Management, LLC
    Passive investor
    at least 4.8%−0.7 pts
    (filed with 7 related holders)
    Since 12 August 2025
    What they said

    Not applicable.

    Read the filing
  • at least 4.6%
    (filed with 1 related holder)
    Since 30 September 2025
  • Venrock Healthcare Capital Partners III, L.P.
    Passive investor
    at least 4.2%−1.6 pts
    (filed with 6 related holders)
    Since 31 March 2026
  • David V Goeddel
    Passive investor
    at least 3.7%
    (filed with 3 related holders)
    Since 30 September 2025
  • FMR LLC
    Passive investor
    at least 3.5%
    (filed with 1 related holder)
    Since 31 December 2024
  • James N. Topper
    Passive investor
    at least 2.0%
    (filed with 12 related holders)
    Since 31 March 2025
  • Sold down below 5%
    Since 31 March 2026
  • Sold down below 5%
    Since 31 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 4 sold $3m, $2m of it under preset trading plans.

  • Heyman Richard A.
    Director
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    6,700
    Price
    $12.91
    Value
    $86,524
  • Piscitelli Dominic
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    28 September 2026
    Shares
    13,400
    Price
    $13.53
    Value
    $181,258
  • Piscitelli Dominic
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    24 September 2026
    Shares
    600
    Price
    $13.50
    Value
    $8,103
  • Piscitelli Dominic
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    26 August 2026
    Shares
    77,000
    Price
    $13.69
    Value
    $1m
  • Heyman Richard A.
    Director
    Sold
    under a preset trading plan
    Date
    24 July 2026
    Shares
    13,100
    Price
    $12.02
    Value
    $157,462
  • Heyman Richard A.
    Director
    Sold
    under a preset trading plan
    Date
    6 July 2026
    Shares
    300
    Price
    $12.00
    Value
    $3,600
  • Piscitelli Dominic
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    24 February 2026
    Shares
    52,000
    Price
    $13.51
    Value
    $702,520
  • Heyman Richard A.
    Director
    Sold
    under a preset trading plan
    Date
    16 January 2026
    Shares
    6,700
    Price
    $12.00
    Value
    $80,400
  • Piscitelli Dominic
    Chief Financial Officer
    Sold
    Date
    16 December 2025
    Shares
    10,720
    Price
    $9.06
    Value
    $97,123
  • Chacko Jacob
    PRESIDENT AND CEO, Director
    Sold
    Date
    16 December 2025
    Shares
    33,374
    Price
    $9.06
    Value
    $302,368

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 23 Feb 2026, plus the 10-Q filed 3 Aug 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.